Thalidomide in agnogenic and secondary myelofibrosis

British Journal of Haematology

Volumn 115, Issue 2, 2001, Pages 313-315

  Canepa, Letizia ^a   Ballerini, Filippo ^a   Varaldo, Riccardo ^a   Quintino, Sabrina ^a   Reni, Lizia ^b   Clavio, Marino ^a   Miglino, Maurizio ^a   Pierri, Ivana ^a   Gobbi, Marco ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Antiangiogenesis; Myelofibrosis; Myeloproliferative disorders; Thalidomide

Indexed keywords

THALIDOMIDE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; EVALUATION; FEMALE; HUMAN; MALE; MYELOFIBROSIS; PRIORITY JOURNAL; TRANSFUSION; TREATMENT FAILURE; TREATMENT OUTCOME;

ADULT; AGED; ANGIOGENESIS INHIBITORS; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBINS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYELOFIBROSIS; MYELOID METAPLASIA; THALIDOMIDE; TREATMENT OUTCOME;

EID: 0035726548     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2001.03072.x     Document Type: Article

References (12)

1. The Italian Consensus Conference on diagnostic criteria for myelofibrosis with myeloid metaplasia
2. Thalidomide in patients with myelofibrosis with myeloid metaplasia
3. Myelofibrosis: Report of five cases treated with thalidomide
4. Thalidomide is an inhibitor of angiogenesis
5. Prognostic factors in agnogenic myeloid metaplasia: A report on 195 cases with a new scoring system
6. Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia
7. Antiangiogenic therapy with thalidomide improves anemia, thrombocytopenia, hyperleukocytosis, splenomegaly in idiopathic myelofibrosis
8. Antitumor activity of thalidomide in refractory multiple myeloma
9. Myelofibrosis with myeloid metaplasia
10. Thalidomide antiangiogenesis therapy (Rx) in Philadelphia (Ph)-negative myeloproliferative disorders (MPD) and myelofibrosis (MF)
11. Clonality in chronic myeloproliferative disorders defined by X-chromosome linked probes: Demonstration of heterogeneity in lineage involvement
12. Myelofibrosis with myeloid metaplasia: Clinical and hematological parameters predicting survival in a series of 133 patients